Literature DB >> 19382216

Omalizumab for treatment of ABPA exacerbations in CF patients.

Patrick Lebecque, Anissa Leonard, Charles Pilette.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19382216     DOI: 10.1002/ppul.21002

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


× No keyword cloud information.
  6 in total

Review 1.  Severe asthma with fungal sensitization.

Authors:  Ritesh Agarwal
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

Review 2.  Omalizumab: Anti-IgE therapy in allergy.

Authors:  Matthias Volkmar Kopp
Journal:  Curr Allergy Asthma Rep       Date:  2011-04       Impact factor: 4.806

3.  Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin e therapy (omalizumab).

Authors:  Mai K Elmallah; Leslie Hendeles; Robert G Hamilton; Cindy Capen; Pamela M Schuler
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

4.  Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.

Authors:  M Proesmans; F Vermeulen; M Vreys; K De Boeck
Journal:  Int J Pediatr       Date:  2010-12-23

5.  Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab.

Authors:  Jennifer Collins; Gabriele Devos; Golda Hudes; David Rosenstreich
Journal:  J Asthma Allergy       Date:  2012-11-08

6.  Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors:  Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal:  Drug Des Devel Ther       Date:  2014-02-07       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.